Acoustic Neuroma will Boost Market at a Strong CAGR of 7.20% during the Forecast Period 2023 - 2030

Pune, India, 2022 /MRFR Press Release/- Market Research Future has a half-cooked research report on the global acoustic neuroma market.

Acoustic Neuroma will Boost Market Highlights

An acoustic neuroma (vestibular schwannoma or acoustic neurinoma) is a non-malignant, usually slow-growing tumor that develops in the inner ear. The tumor is the results of overproduction of Schwann cells, the cells that are around nerve fibers to help support nerves. Early diagnosis of an acoustic neuroma is key to preventing its serious consequences. The 3 treatment options are surgical removal, radiation, and monitoring. Typically, the tumor is surgically removed. The type of operation involved, depends on the size of the tumor and the level of hearing remaining in the affected ear. An alternative to conventional surgeries are radiosurgery with a gamma knife or linear accelerator which may be employed to reduce the size or limit the growth of the tumor.

The Acoustic Neuroma Market is projected to reach USD 2.37 Billion by 2030 at 7.20% CAGR during the forecast period 2023-2030.

Currently, these tumors are treated with surgery or radiation. But few anti-cancer drug such as bevacizumab (avastin) an designed to reduce blood flow to tumors in order to shrink them are also used to treat these tumors.

Regional Analysis

Global acoustic neuroma consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East.

North America dominated the global acoustic neuroma market owing to the increasing research and development in pharmaceutical companies and rising awareness about brain tumors are playing a significant role in driving the global acoustic neuroma market. In addition to this, companies are constantly focusing on more refined diagnostic and testing procedures, which is helping to start the advent of personalized medicine and enabling physicians to make more informed therapy decisions. The incident rate in the U.S. in 2010 was 11/1,000,000 individuals, mean age 53. The occurrence was equally distributed versus age, gender and laterality. In patients with unilateral hearing loss, only about 1 in 1000 has acoustic neuroma. The European market is growing at a steady pace and is anticipated to compete with the American market. Asia Pacific is expected to be the fastest growing region in the acoustic neuroma market during the forecasted period.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Acoustic Neuroma Market Research Report

Segmentation

The acoustic neuroma is segmented on the basis of type, diagnosis, drug class, treatment, and end-users.

On the basis of type, the market is segmented into unilateral vestibular schwannomas and bilateral vestibular schwannomas.

On the basis of diagnosis, the market is segmented into hearing test (audiometry), electronystagmography, magnetic resonance imaging (MRI), and others.

On the basis of drug class, the market is segmented into anticonvulsants, corticosteroids, osmotic diuretics and pain killers.

On the basis of treatment, the market is segmented into monitoring, surgery, radiation therapy, supportive therapy and others. The radiation therapy is sub segmented stereotactic radiotherapy, proton beam therapy. Surgery is subsegmented radiosurgery, craniotomy, and microsurgery removal

On the basis of end-user, the market is segmented into hospitals, diagnostic centers, academic and research institutes, and others.

Key Players

Some of key the players in the global acoustic neuroma market are GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), F. Hoffmann-La Roche Ag, Merck & Co., Inc., Novartis AG, Pfizer Inc., and others